Difference between revisions of "Team:EPFL"

 
(31 intermediate revisions by 4 users not shown)
Line 4: Line 4:
 
<body>
 
<body>
  
−
    <main>
+
  <main>
−
        <section class="spotlight bg-primary bg-cover bg-size--cover" data-spotlight="fullscreen" style="background-color #f03;">
+
 
−
            <span class="mask bg-primary alpha-4"></span>
+
 
−
            <div class="spotlight-holder py-lg pt-lg-xl">
+
 
−
                <div class="container d-flex align-items-center">
+
 
−
                    <div class="col">
+
    <!-- Spotlight -->
−
                        <div class="row cols-xs-space align-items-end text-center text-md-left justify-content-center">
+
    <section class="slice slice-xl bg-dark">
−
                            <div class="col-lg-7">
+
      <div class="container">
−
                                <div class="text-center">
+
        <div class="row row-grid align-items-center">
−
                                    <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--LOGO_INVERT.png" style="width: 200px;">
+
          <div class="col-lg-5">
−
                                    <h2 class="text-white my-4">
+
            <div class="pt-lg-lg pb-lg-sm text-center text-lg-left">
−
                      <span class="display-4 font-weight-bold">CAPOEIRA</span>
+
              <h2 class="h1 text-white mb-3">CAPOEIRA</h2>
−
                    </h2>
+
              <p class="lead text-white lh-180">CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay</p>
−
                                    <p class="lead text-white">Cancer Personalized Encapsulin Immunotherapy and Relapse Assay</p>
+
 
−
                                    <div class="mt-5">
+
                          <a href="https://2018.igem.org/Team:EPFL/Description" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me">
−
                                        <a href="https://2018.igem.org/Team:EPFL/Description" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me">
+
 
−
                                            <span class="btn-inner--text">Learn more about our project</span>
+
                                      <span class="btn-inner--text">Learn more about our project</span>
−
                                            <span class="btn-inner--icon"><i class="fas fa-angle-right"></i></span>
+
                                      <span class="btn-inner--icon"><i class="fas fa-angle-right"></i></span>
−
                                        </a>
+
                                  </a>
−
                                    </div>
+
−
                                </div>
+
−
                            </div>
+
−
                        </div>
+
−
                    </div>
+
−
                </div>
+
 
             </div>
 
             </div>
 +
          </div>
 +
          <div class="col-lg-6 ml-lg-auto text-center">
 +
            <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--LOGO_INVERT.png" style="width: 300px;">
 +
          </div>
 +
        </div>
 +
      </div>
 +
      <div class="shape-container" data-shape-style="curve" data-shape-position="bottom">
 +
        <svg class="shape-fill-primary" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1000 100" preserveAspectRatio="none">
 +
                <path d="M 0 0 c 0 0 200 50 500 50 s 500 -50 500 -50 v 101 h -1000 v -100 z"></path>
 +
            </svg>
 +
      </div>
 +
    </section>
 +
 +
 +
 +
 +
 +
    <section class="slice slice-xl bg-primary" id="CAP">
 +
      <div class="container">
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-12">
 +
            <div class="pr-md-4">
 +
              <h3 class="heading h3 text-white text-center"><font size="+2">What is CAPOEIRA ?</font></h2>
 +
              <p class="lead text-white my-4">While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project
 +
                “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance.
 +
                First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments
 +
                presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential
 +
                relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
 +
 +
              </p>
 +
            </div>
 +
          </div>
 +
 +
          <div class="p-5 rounded bg-primary">
 
             <a href="#abstract" class="tongue tongue-bottom scroll-me"><i class="fas fa-angle-down"></i></a>
 
             <a href="#abstract" class="tongue tongue-bottom scroll-me"><i class="fas fa-angle-down"></i></a>
−
         </section>
+
          </div>
−
        <section id="abstract" class="slice">
+
 
−
            <div class="container">
+
         </div>
−
                <div class="mb-5 text-center">
+
      </div>
−
                    <h3 class="heading h3">What is CAPOEIRA ?</h3>
+
    </section>
−
                    <div class="text-center mt-4">
+
 
−
                        <p class="lead lh-180">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of its therapy. Immunooncological approaches to treatment are becoming ever more important, with immunotherapy harnessing the immune system's existing weapons in the fight against malignancy. The project that the 2018 EPFL iGEM team presents is focused on developing new techniques for treating melanoma, the deadliest form of skin cancer, by providing a set of tools to identify promising targets, rapidly manufacture an array of corresponding vaccines, and detect potential cancer relapse all on a personalized basis. The project is exhaustive and can be divided into the following parts:</p>
+
 
−
                    </div>
+
 
−
                </div>
+
    <section id="abstract" class="slice">
−
                <div class="row justify-content-center">
+
      <div class="container">
−
                    <div class="col-lg-10">
+
        <div class="mb-5 text-center">
−
                        <div class="timeline" data-timeline-axis-style="dashed" data-timeline-axis-color="light" data-timeline-content="axis">
+
          <br>
−
                            <div class="timeline-block">
+
          <h3 class="heading h3"><font size="+5">This is CAPOEIRA</font></h2>
−
                                <span class="timeline-axis-step box-shadow-1 text-primary"><i class="fas fa-search fa-2x"></i></span>
+
        </div>
−
                                <div class="timeline-content">
+
 
−
                                    <div class="">
+
 
−
                                        <h3 class="h5">Detection</h3>
+
        <div class="row row-grid align-items-center slice slice-lg">
−
                                        <p>Detection of cancer patient specific tumor mutations and neoantigens</p>
+
          <div class="col-lg-5">
−
                                    </div>
+
            <div class="animate-this">
−
                                </div>
+
            <img src="https://static.igem.org/mediawiki/2018/0/01/T--EPFL--bioinfo.svg" class="img-center img-fluid" width="300px">
−
                            </div>
+
          </div>
−
                            <div class="timeline-block mt-5">
+
          </div>
−
                                <span class="timeline-axis-step box-shadow-1 text-primary"><i class="fas fa-syringe  fa-2x"></i></span>
+
          <div class="col-lg-7 ml-lg-auto">
−
                                <div class="timeline-content">
+
            <div>
−
                                    <div class="">
+
              <h2 class="text-center"><font size="+2">Bioinformatics</font></h2>
−
                                        <h3 class="h5">Vaccine</h3>
+
              <p class="lead text-gray my-4 text-center">
−
                                        <p>Expression of the neoantigens and the adjuvant using encapsulin</p>
+
                <font size="+2">First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells</font>
−
                                    </div>
+
              </p>
−
                                </div>
+
 
−
                            </div>
+
−
                            <div class="timeline-block mt-5">
+
−
                                <span class="timeline-axis-step box-shadow-1 text-primary"><i class="fas fa-flask fa-2x"></i></span>
+
−
                                <div class="timeline-content">
+
−
                                    <div class="">
+
−
                                        <h3 class="h5">Immune response</h3>
+
−
                                        <p>Maturation of dendritic cells and T-cells</p>
+
−
                                    </div>
+
−
                                </div>
+
−
                            </div>
+
−
                            <div class="timeline-block mt-5">
+
−
                                <span class="timeline-axis-step box-shadow-1 text-primary"><i class="fas fa-notes-medical fa-2x"></i></span>
+
−
                                <div class="timeline-content">
+
−
                                    <div class="">
+
−
                                        <h3 class="h5">Follow up</h3>
+
−
                                        <p>Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA</p>
+
−
                                    </div>
+
−
                                </div>
+
−
                            </div>
+
−
                        </div>
+
−
                    </div>
+
−
                </div>
+
 
             </div>
 
             </div>
−
         </section>
+
          </div>
 +
         </div>
 +
        <br>
 +
        <div class="row row-grid align-items-center slice slice-lg">
 +
          <div class="col-lg-5 order-lg-2 ml-lg-auto">
 +
            <img src="https://static.igem.org/mediawiki/2018/b/b2/T--EPFL--vaccine-logo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 order-lg-1">
 +
            <div class="pr-lg-7">
 +
              <h2 class="text-center"><font size="+2">Vaccine</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-5">
 +
            <img src="https://static.igem.org/mediawiki/2018/4/4a/T--EPFL--DCentier.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 ml-lg-auto">
 +
            <div>
 +
              <h2 class="text-center"><font size="+2">Dendritic cell Activation</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells</font>
 +
              </p>
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-5 order-lg-2 ml-lg-auto">
 +
            <img src="https://static.igem.org/mediawiki/2018/3/3d/T--EPFL--follow_up_logo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 order-lg-1">
 +
            <div class="pr-lg-7">
 +
              <h2 class="text-center"> <font size="+2">Follow-up</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
<hr style="height:2px;border:none;color:#333;background-color:#333;" >
 +
      </div>
 +
 
 +
 
 +
 
 +
      <section class="slice slice-xl bg-cover bg-size--cover" style="background-image: url('https://static.igem.org/mediawiki/2018/4/4f/T--EPFL--TeamPage.jpeg'); background-position: center top;">
 +
          <div class="container">
 +
              <div class="row justify-content-center">
 +
                  <div class="col-lg-9">
 +
                      <div class="text-center">
 +
                          <h2 class="heading h1 text-white"> </br> </br> </br> Won: <span>Gold Medal</span></br> Nominated for: <span>Best Therapeutic Project</span> and <span>Best Software</br></ul></ui></h2>
 +
                          <div class="btn-container mt-5">
 +
                              <a href="https://2018.igem.org/Team:EPFL/Awards" class="btn btn-white btn-primary btn-circle px-5">Our Awards!</a>
 +
                          </div>
 +
                      </div>
 +
                  </div>
 +
              </div>
 +
          </div>
 +
      </section>
 +
      <div class="container">
 +
 
 +
<hr style="height:2px;border:none;color:#333;background-color:#333;" >
 +
 
 +
      <div class="row">
 +
<video class="responsive-video center-margin" style="width: 100%; padding: 30px" controls>
 +
              <source src="https://static.igem.org/mediawiki/2018/7/77/T--EPFL--iGEM_2018_video.mp4" type="video/mp4" >
 +
              </video>
 +
      </div>
 +
 
 +
 
 +
    </div>
 +
 
 +
 
 +
    </section>
  
−
    </main>
+
  </main>
 
</body>
 
</body>
  
 
</html>
 
</html>
 
{{EPFL/Footer}}
 
{{EPFL/Footer}}

Latest revision as of 00:21, 8 December 2018

iGEM EPFL 2018

CAPOEIRA

CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay

Learn more about our project

What is CAPOEIRA ?

While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!


This is CAPOEIRA

Bioinformatics

First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells


Vaccine

Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes

Dendritic cell Activation

This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells

Follow-up

Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA




Won: Gold Medal
Nominated for: Best Therapeutic Project and Best Software

Our Awards!